Mandate

Vinge has advised Vicore Pharma in connection with a directed share issue of approximately SEK 185 million

Vinge has advised Vicore Pharma, a Swedish rare disease company focused on interstitial lung diseases and related indications, in connection with a directed share issue whereby Vicore Pharma will receive approximately SEK 185 million in issue proceeds.

The subscription price was determined to SEK 18.50 per share through an accelerated book building process. The share issue was directed to a number of Swedish and international institutional investors. The main purpose of the share issue is to finance Vicore Pharma’s development of current and future product candidates.

Vinge’s team consisted of Jesper Schönbeck, Rikard Lindahl, William Kåge and Clara Sohlberg.

 

Related

Vinge has advised Stendörren Fastigheter in connection with a directed share issue of approximately SEK 300 million

Vinge has advised the property company Stendörren Fastigheter AB (publ) in connection with a directed share issue through which the company raises proceeds of approximately SEK 300 million before transaction costs.
May 14, 2025

Vinge has advised EQT AB in connection with its bond issue in the aggregate principal amount of USD 500,000,000

EQT AB (publ) has issued senior bonds in the aggregate principal amount of USD 500,000,000 with an interest rate of 5.850%, due 2035, at a price equal to 99.783% of the aggregate principal amount thereof.
May 13, 2025

Vinge has advised Qlik in connection with acquisition

Vinge has advised the Qlik Group in connection with its acquisition of the Qloud Cover Migration technology from Stretch Qonnect. This automated solution, to be branded as the Qlik Analytics Migration Tool, eliminates the complexity of migrating from QlikView, Qlik Sense, and NPrinting to Qlik Cloud – a persistent barrier to cloud adoption.
May 13, 2025